• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/8/21 4:54:44 PM ET
    $FPRX
    Major Pharmaceuticals
    Health Care
    Get the next $FPRX alert in real time by email
    SC 13G/A 1 sc13ga107422fprx_03082021.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Five Prime Therapeutics, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001

     (Title of Class of Securities)

    33830X104

     (CUSIP Number)

    March 4, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,372,098  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,372,098  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,372,098  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.3%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 33830X104

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,372,098  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,372,098  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,372,098  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.3%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,484,643  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,484,643  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,484,643  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,484,643  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              2,484,643  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,484,643  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         405,344  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              405,344  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            405,344  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         405,344  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              405,344  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            405,344  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         5,856,741  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              5,856,741  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            5,856,741  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            12.8%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,338,678  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              6,338,678  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,338,678  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            13.8%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,338,678  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              6,338,678  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,338,678  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            13.8%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. 33830X104

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         6,338,678  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              6,338,678  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            6,338,678  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            13.8%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. 33830X104

    Item 1(a).Name of Issuer:

    Five Prime Therapeutics, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    111 Oyster Point Boulevard

    South San Francisco, California 94080

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware 

    12

    CUSIP No. 33830X104

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    33830X104

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. 33830X104

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on March 8, 2021, (i) BVF beneficially owned 3,372,098 Shares, (ii) BVF2 beneficially owned 2,484,643 Shares and (iii) Trading Fund OS beneficially owned 405,344 Shares.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 3,372,098 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 2,484,643 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 405,344 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 5,856,741 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 6,338,678 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the “Partners Managed Account”), including 76,593 Shares held in the Partners Managed Account.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 6,338,678 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 6,338,678 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

     

    (b)Percent of class:

     

    The following percentages are based on 45,939,508 Shares outstanding as of March 1, 2021, which is the total number of Shares outstanding as disclosed in that certain Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and the Issuer filed as Exhibit 2.1 to the Issuer’s Current Report on Form 8-K with the Securities and Exchange Commission on March 4, 2021.

     

    14

    CUSIP No. 33830X104

    As of the close of business on March 8, 2021, (i) BVF beneficially owned approximately 7.3% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 5.4% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 7.3% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 5.4% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 12.8% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 13.8% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and the Partners Managed Account.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on February 1, 2021.

     

    15

    CUSIP No. 33830X104

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    16

    CUSIP No. 33830X104

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: March 8, 2021

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

    17

     

    Get the next $FPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FPRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

      THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

      4/16/21 8:25:00 AM ET
      $FPRX
      $AMGN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission. About Five Prime Therapeutics Five Prime is a clinical stage biotech

      3/9/21 5:00:00 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 8:04:26 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 7:57:02 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability

      4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)

      4/19/21 7:53:58 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Five Prime Therapeutics with a new price target

      Guggenheim resumed coverage of Five Prime Therapeutics with a rating of Neutral and set a new price target of $38.00

      3/15/21 8:09:30 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • Jefferies Financial Group resumed coverage on Five Prime Therapeutics with a new price target

      Jefferies Financial Group resumed coverage of Five Prime Therapeutics with a rating of Hold and set a new price target of $38.00

      3/10/21 8:10:17 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • Five Prime Therapeutics downgraded by Guggenheim with a new price target

      Guggenheim downgraded Five Prime Therapeutics from Buy to Neutral and set a new price target of $38.00

      3/9/21 6:56:49 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Five Prime Therapeutics, Inc.

      SC 13D - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/15/21 6:33:20 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/8/21 4:54:44 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      3/1/21 5:00:03 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care

    $FPRX
    Financials

    Live finance-specific insights

    See more
    • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

      THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

      4/16/21 8:25:00 AM ET
      $FPRX
      $AMGN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

      SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

      1/4/22 8:00:00 AM ET
      $FACT
      $FPRX
      $PDLI
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $FPRX
    SEC Filings

    See more
    • SEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)

      SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)

      5/17/21 4:34:51 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Five Prime Therapeutics, Inc.

      15-12B - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

      4/26/21 4:11:57 PM ET
      $FPRX
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Five Prime Therapeutics, Inc.

      EFFECT - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)

      4/22/21 12:15:14 AM ET
      $FPRX
      Major Pharmaceuticals
      Health Care